{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T20:43:39Z","timestamp":1794948219268,"version":"4.9.1"},"reference-count":90,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n            <jats:title>Learning Objectives:<\/jats:title>\n            <jats:p>After reading this article and viewing the videos, the participant should be able to: 1. Discuss margins for in situ and invasive disease and describe reconstructive options for wide excision defects, including the keystone flap. 2. Describe a digit-sparing alternative for subungual melanoma. 3. Calculate personalized risk estimates for sentinel node biopsy using predictive nomograms. 4. Describe the indications for lymphadenectomy and describe a technique intended to reduce the risk of lymphedema following lymphadenectomy. 5. Offer options for in-transit melanoma management.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary:<\/jats:title>\n            <jats:p>Melanoma management continues to evolve, and plastic surgeons need to stay at the forefront of advances and controversies. Appropriate margins for in situ and invasive disease require consideration of the trials on which they are based. A workhorse reconstruction option for wide excision defects, particularly in extremities, is the keystone flap. There are alternative surgical approaches to subungual tumors besides amputation. It is now possible to personalize a risk estimate for sentinel node positivity beyond what is available for groups of patients with a given stage of disease. Sentinel node biopsy can be made more accurate and less morbid with novel adjuncts. Positive sentinel node biopsies are now rarely managed with completion lymphadenectomy. Should a patient require lymphadenectomy, immediate lymphatic reconstruction may mitigate the lymphedema risk. Finally, there are minimally invasive modalities for effective control of in-transit recurrences.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/prs.0000000000009936","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T19:02:18Z","timestamp":1677178938000},"page":"495e-505e","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Current Controversies in Melanoma Treatment"],"prefix":"10.1097","volume":"151","author":[{"given":"Claire","family":"Temple-Oberle","sequence":"first","affiliation":[{"name":"From the Clinical Department of Oncology, Calgary Zone, Section of Surgical Oncology, Tom Baker Cancer Centre."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Nicholas","sequence":"additional","affiliation":[{"name":"From the Clinical Department of Oncology, Calgary Zone, Section of Surgical Oncology, Tom Baker Cancer Centre."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscila","family":"Rojas-Garcia","sequence":"additional","affiliation":[{"name":"From the Clinical Department of Oncology, Calgary Zone, Section of Surgical Oncology, Tom Baker Cancer Centre."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"key":"R1-20250501","first-page":"2015","article-title":"Melanoma staging: American Joint Committee on Cancer (AJCC) 8th Edition and beyond.","volume":"25","author":"Gershenwald","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"R2-20250501","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1245\/s10434-018-6470-1","article-title":"1 versus 2-cm excision margins for pT2-pT4 primary cutaneous melanoma (MelMarT): a feasibility study.","volume":"25","author":"Moncrieff","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"R3-20250501","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma.","volume":"376","author":"Faries","year":"2017","journal-title":"N Engl J Med"},{"key":"R4-20250501","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3892\/or.2021.8109","article-title":"The role of immunotherapy and molecular-targeted therapy in the treatment of melanoma (review).","volume":"46","author":"Stachyra-Strawa","year":"2021","journal-title":"Oncol Rep"},{"key":"R5-20250501","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1046\/j.1365-2230.2000.00691.x","article-title":"Surgical management of primary melanoma.","volume":"25","author":"Kaufmann","year":"2000","journal-title":"Clin Exp Dermatol"},{"key":"R6-20250501","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1245\/s10434-019-07866-y","article-title":"The landmark series: randomized trials examining surgical margins for cutaneous melanoma.","volume":"27","author":"Angeles","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"R7-20250501","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1245\/s10434-019-08015-1","article-title":"ASO author reflections: surgical margins for melanoma\u2014what\u2019s ext?","volume":"27","author":"Angeles","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"R8-20250501","doi-asserted-by":"crossref","first-page":"367","DOI":"10.6004\/jnccn.2019.0018","article-title":"Cutaneous melanoma, version 2.2019, NCCN clinical practice guidelines in oncology.","volume":"17","author":"Coit","year":"2019","journal-title":"J Natl Compr Cancer Netw"},{"key":"R9-20250501","doi-asserted-by":"crossref","first-page":"e541","DOI":"10.3747\/co.26.4885","article-title":"Primary excision margins, sentinel lymph node biopsy, and completion lymph node dissection in cutaneous melanoma: a clinical practice guideline.","volume":"26","author":"Wright","year":"2019","journal-title":"Curr Oncol"},{"key":"R10-20250501","first-page":"599","article-title":"Comparison of surgical margins for lentigo maligna versus melanoma in situ.","volume":"370","author":"Kunishige","journal-title":"N Engl J Med"},{"key":"R11-20250501","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2147\/CCID.S224738","article-title":"Lentigo maligna: clinical presentation and appropriate management.","volume":"13","author":"Iznardo","year":"2020","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R12-20250501","first-page":"e2020018","article-title":"Defining surgical margins with Wood lamp.","volume":"10","author":"Atwan","year":"2020","journal-title":"Dermatol Pract Concept"},{"key":"R13-20250501","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/jso.20305","article-title":"Mohs micrographic surgery in the treatment of lentigo maligna and melanoma.","volume":"94","author":"Temple","year":"2006","journal-title":"J Surg Oncol"},{"key":"R14-20250501","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1111\/dsu.12335","article-title":"Comparison of outcomes for malignant melanoma of the face treated using Mohs micrographic surgery and wide local excision.","volume":"39","author":"Chin-Lenn","year":"2013","journal-title":"Dermatol Surg"},{"key":"R15-20250501","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2147\/CCID.S137513","article-title":"Current perspectives on Mohs micrographic surgery for melanoma.","volume":"11","author":"Beauliew","year":"2018","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R16-20250501","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/jso.20284","article-title":"The perimeter technique for lentigo maligna: an alternative to Mohs micrographic surgery.","volume":"91","author":"Mahoney","year":"2005","journal-title":"Surg Oncol"},{"key":"R17-20250501","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/1203475420952425","article-title":"Outcomes of staged excision with circumferential en face margin control for lentigo maligna of the head and neck.","volume":"25","author":"Liu","year":"2021","journal-title":"Cutan Med Surg"},{"key":"R18-20250501","doi-asserted-by":"crossref","first-page":"565","DOI":"10.5999\/aps.2012.39.5.565","article-title":"Management of malignant melanoma.","volume":"39","author":"Mun","year":"2012","journal-title":"Arch Plast Surg"},{"key":"R19-20250501","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/PRS.0000000000000529","article-title":"Subungual melanoma: a review of current treatment.","volume":"134","author":"Cochran","year":"2014","journal-title":"Plast Reconstr Surg"},{"key":"R20-20250501","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.jaad.2019.06.012","article-title":"Functional surgery versus amputation for in situ or minimally invasive nail melanoma: a meta-analysis.","volume":"81","author":"Jo","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R21-20250501","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1590\/abd1806-4841.201645100","article-title":"Conservative surgical management of in situ subungual melanoma: long-term follow-up.","volume":"91","author":"Anda-Ju\u00e1rez","year":"2016","journal-title":"An Bras Dermatol"},{"key":"R22-20250501","doi-asserted-by":"crossref","first-page":"e2698","DOI":"10.1097\/GOX.0000000000002698","article-title":"Acral lentiginous melanoma: do surgical approach and sentinel lymph node biopsy matter?","volume":"8","author":"Walker","year":"2020","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"R23-20250501","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/jdv.16121","article-title":"Melanoma of the nail apparatus: a systematic review and meta-analysis of current challenges and prognosis.","volume":"34","author":"Lieberherr","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R24-20250501","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1186\/s12885-019-6248-2","article-title":"Confirmatory trial of non-amputative digit preservation surgery for subungual melanoma: Japan Clinical Oncology Group study (JCOG1602, J-NAIL study protocol).","volume":"19","author":"Tanaka","year":"2019","journal-title":"BMC Cancer"},{"key":"R25-20250501","doi-asserted-by":"crossref","first-page":"6343","DOI":"10.1097\/PRS.0000000000008391","article-title":"Fine details that improve nasal reconstruction.","volume":"148","author":"Borsuk","year":"2021","journal-title":"Plast Reconstr Surg"},{"key":"R26-20250501","doi-asserted-by":"crossref","first-page":"710e","DOI":"10.1097\/PRS.0000000000002610","article-title":"The concepts of propellor, perforator, keystone, and other local flaps and their role in the evolution of reconstruction.","volume":"138","author":"Mohan","year":"2016","journal-title":"Plast Reconstr Surg"},{"key":"R27-20250501","doi-asserted-by":"crossref","first-page":"895e","DOI":"10.1097\/PRS.0000000000001146","article-title":"Surgical treatment and reconstruction of nonmelanoma facial skin cancers.","volume":"135","author":"Rogers-Vizena","year":"2015","journal-title":"Plast Reconstr Surg"},{"key":"R28-20250501","doi-asserted-by":"crossref","first-page":"796e","DOI":"10.1097\/PRS.0000000000007331","article-title":"Best new flaps and tips for success in microsurgery.","volume":"146","author":"Brown","year":"2020","journal-title":"Plast Reconstr Surg"},{"key":"R29-20250501","doi-asserted-by":"crossref","first-page":"e2774","DOI":"10.1097\/GOX.0000000000002774","article-title":"Best local flaps for lower extremity reconstruction.","volume":"8","author":"AlMugaren","year":"2020","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"R30-20250501","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/PRS.0000000000001449","article-title":"Avoiding skin grafts: the keystone flap in cutaneous defects.","volume":"136","author":"Stone","year":"2015","journal-title":"Plast Reconstr Surg"},{"key":"R31-20250501","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1046\/j.1445-2197.2003.02638.x","article-title":"The keystone design perforator island flap in reconstructive surgery.","volume":"73","author":"Behan","year":"2003","journal-title":"ANZ J Surg"},{"key":"R32-20250501","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.bjps.2009.06.028","article-title":"Extended experience and modifications in the design and concepts of the keystone design island flap.","volume":"63","author":"Moncrieff","year":"2010","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"R33-20250501","doi-asserted-by":"crossref","first-page":"535","DOI":"10.5999\/aps.2020.00094","article-title":"A systematic review of the keystone design perforator island flap in the reconstruction of trunk defects.","volume":"47","author":"Rini","year":"2020","journal-title":"Arch Plast Surg"},{"key":"R34-20250501","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1097\/SCS.0000000000002742","article-title":"Keystone perforator island flap as an alternative reconstructive option for partial thickness alar defects up to 1.5 centimeters.","volume":"27","author":"Kostopoulos","year":"2016","journal-title":"J Craniofac Surg"},{"key":"R35-20250501","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2217\/fon.14.300","article-title":"Radiotherapy for cutaneous melanoma: current and future applications.","volume":"11","author":"Gorayski","year":"2015","journal-title":"Future Oncol"},{"key":"R36-20250501","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1470-2045(15)00187-4","article-title":"Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02\/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial.","volume":"16","author":"Henderson","year":"2015","journal-title":"Lancet Oncol"},{"key":"R37-20250501","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijrobp.2020.06.006","article-title":"Adjuvant nodal radiation therapy for melanoma in the era of immunotherapy.","volume":"108","author":"Mitra","year":"2020","journal-title":"Int J Radiat Oncol Bio Phys"},{"key":"R38-20250501","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1245\/s10434-020-09384-8","article-title":"Adjuvant radiation therapy for clinical stage III melanoma in the modern therapeutic era.","volume":"28","author":"Straker","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"R39-20250501","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.ejso.2017.07.003","article-title":"Complications following completion lymphadenectomy versus therapeutic lymphadenectomy for melanoma: a systematic review of the literature.","volume":"43","author":"Moody","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"R40-20250501","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jss.2013.04.033","article-title":"Sartorius transposition during inguinal lymphadenectomy for melanoma.","volume":"184","author":"Bartlett","year":"2013","journal-title":"J Surg Res"},{"key":"R41-20250501","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2217\/mmt-2016-0023","article-title":"Lymph node dissection for melanoma: where do we stand?","volume":"4","author":"Neuwirth","year":"2017","journal-title":"Melanoma Manag"},{"key":"R42-20250501","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1310460","article-title":"Final trial report of sentinel-node biopsy versus nodal observation in melanoma.","volume":"370","author":"Morton","year":"2014","journal-title":"N Engl J Med"},{"key":"R43-20250501","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1200\/JCO.2017.75.7724","article-title":"Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American Society of Clinical Oncology and Society of Surgical Oncology clinical practice guideline update.","volume":"36","author":"Wong","year":"2018","journal-title":"J Clin Oncol"},{"key":"R44-20250501","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1245\/ASO.2005.05.016","article-title":"A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American Joint Committee on Cancer staging system.","volume":"12","author":"Wong","year":"2005","journal-title":"Ann Surg Oncol"},{"key":"R45-20250501","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1200\/JCO.19.02362","article-title":"Improved risk prediction calculator for sentinel node positivity in patients with melanoma: the Melanoma Institute Australia nomogram.","volume":"38","author":"Lo","year":"2020","journal-title":"J Clin Oncol"},{"key":"R46-20250501","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1200\/JCO.19.01902","article-title":"Factors affecting sentinel node metastasis in thin (T1) cutaneous melanomas: development and external validation of a predictive nomogram.","volume":"14","author":"Maurichi","year":"2020","journal-title":"J Clin Oncol"},{"key":"R47-20250501","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1245\/s10434-010-1054-8","article-title":"Creating and providing predictions of melanoma outcome.","author":"Tanabe","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"R49-20250501","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/archsurg.1992.01420040034005","article-title":"Technical details of intraoperative lymphatic mapping for early stage melanoma.","volume":"127","author":"Morton","year":"1992","journal-title":"Arch Surg"},{"key":"R50-20250501","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/bjs.1800811220","article-title":"Gamma probe-guided sentinel node biopsy to select patients with melanoma for lymphadenectomy.","volume":"81","author":"van der Veen","year":"1994","journal-title":"Br J Surg"},{"key":"R51-20250501","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1097\/RLU.0000000000001370","article-title":"Sentinel lymph node biopsy in cutaneous melanoma: standard and new technical procedures and clinical advances. A systematic review of the literature.","volume":"41","author":"Tardelli","year":"2016","journal-title":"Clin Nucl Med"},{"key":"R52-20250501","first-page":"7","article-title":"Failure of radiotracer migration: salvaging sentinel lymph node biopsy in melanoma care with indocyanine green.","author":"Nicholas","year":"2021","journal-title":"Plast Surg Case Stud"},{"key":"R53-20250501","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1016\/j.bjps.2007.12.074","article-title":"Sentinel lymph node detection in skin cancer patients using real-time fluorescence navigation with indocyanine green: preliminary experience.","volume":"62","author":"Fujiwara","year":"2009","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"R54-20250501","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1245\/s10434-019-07617-z","article-title":"Indocyanine green fluorescence imaging with lymphoscintigraphy for sentinel node biopsy in melanoma: increasing the sentinel lymph node-positive rate.","volume":"26","author":"Knackstedt","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"R55-20250501","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1684\/ejd.2010.1237","article-title":"Sentinel lymph node biopsy guided by indocyanine green fluorescence for cutaneous melanoma.","volume":"21","author":"Namikawa","year":"2011","journal-title":"Eur J Dermatol"},{"key":"R56-20250501","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1097\/PRS.0000000000000006","article-title":"Indocyanine green SPY elite\u2013assisted sentinel lymph node biopsy in cutaneous melanoma.","volume":"133","author":"Korn","year":"2014","journal-title":"Plast Reconstr Surg"},{"key":"R57-20250501","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/jso.23745","article-title":"Indocyanine green and fluorescence lymphangiography for sentinel lymph node identification in cutaneous melanoma: indocyanine green for SLN biopsy.","volume":"110","author":"Cloyd","year":"2014","journal-title":"J Surg Oncol"},{"key":"R58-20250501","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.ejso.2020.10.027","article-title":"The use of indocyanine green and near-infrared fluorescence imaging to assist sentinel lymph node biopsy in cutaneous melanoma: a systematic review.","volume":"47","author":"Lafreniere","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"R59-20250501","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/1346-8138.12158","article-title":"Improvement of the sentinel lymph node detection rate of cervical sentinel lymph node biopsy using real-time fluorescence navigation with indocyanine green in head and neck skin cancer.","volume":"40","author":"Nakamura","year":"2013","journal-title":"J Dermatol"},{"key":"R60-20250501","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s10147-013-0524-y","article-title":"Limitation of indocyanine green fluorescence in identifying sentinel lymph node prior to skin incision in cutaneous melanoma.","volume":"19","author":"Namikawa","year":"2014","journal-title":"Int J Clin Oncol"},{"key":"R61-20250501","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.18.02306","article-title":"Final analysis of DeCOG-SLT trial: no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node.","volume":"37","author":"Leiter","year":"2019","journal-title":"J Clin Oncol"},{"key":"R62-20250501","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1002\/cncr.33483","article-title":"Active surveillance of patients who have sentinel node positive melanoma: an international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2).","volume":"127","author":"Broman","year":"2021","journal-title":"Cancer"},{"key":"R63-20250501","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jamcollsurg.2020.11.014","article-title":"Surveillance of sentinel node positive melanoma patients with reasons for exclusion from MSLT-II: multi-institutional propensity score matched analysis.","volume":"232","author":"Broman","year":"2021","journal-title":"J Am Coll Surg"},{"key":"R64-20250501","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.amjsurg.2015.08.014","article-title":"Risk factors associated with lymphedema after lymph node dissection in melanoma patients.","volume":"210","author":"Friedman","year":"2015","journal-title":"Am J Surg"},{"key":"R65-20250501","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1089\/lrb.2017.0067","article-title":"Effect of lymphaticovenous anastomosis in breast cancer-related lymphedema: a review of the literature.","volume":"16","author":"Cornelissen","year":"2018","journal-title":"Lymphat Res Biol"},{"key":"R66-20250501","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s10147-005-0518-5","article-title":"Treatment of lymphedema with lymphaticovenular anastomoses.","volume":"10","author":"Nagase","year":"2005","journal-title":"Int J Clin Oncol"},{"key":"R67-20250501","author":"Jorgensen MG, Toyserkani NM, Sorensen JA. The effect of prophylactic lymphovenous anastomosis and shunts for preventing cancer-related lymphedema: a systematic review and meta-analysis. Microsurgery 2018;38:576\u2013585."},{"key":"R68-20250501","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.bjps.2019.01.023","article-title":"Multiple lymphatic-venous anastomoses in reducing the risk of lymphedema in melanoma patients undergoing complete lymph node dissection. A retrospective case-control study.","volume":"72","author":"Nacchiero","year":"2019","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"R69-20250501","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/j.1445-2197.2008.04716.x","article-title":"Ilioinguinal lymph node dissection for palpable metastatic melanoma to the groin.","volume":"78","author":"Allan","year":"2008","journal-title":"ANZ J Surg"},{"key":"R70-20250501","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma.","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"R71-20250501","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomized, controlled, phase III trial.","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"key":"R72-20250501","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma.","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"R73-20250501","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol"},{"key":"R74-20250501","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1200\/JCO.20.02110","article-title":"Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG\/KEYNOTE-054 trial.","volume":"38","author":"Eggermont","year":"2020","journal-title":"J Clin Oncol"},{"key":"R75-20250501","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.18.01219","article-title":"Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAFV600-mutant stage III melanoma.","volume":"36","author":"Hauschild","year":"2018","journal-title":"J Clin Oncol"},{"key":"R76-20250501","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma.","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"R77-20250501","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1245\/s10434-011-1624-4","article-title":"Surgical prevention of arm lymphedema after breast cancer treatment.","volume":"18","author":"Boccardo","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"R78-20250501","first-page":"20","article-title":"Surgical prevention and treatment of lymphedema after lymph node dissection in patients with cutaneous melanoma.","volume":"46","author":"Boccardo","year":"2013","journal-title":"Lymphology"},{"key":"R79-20250501","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1055\/s-0039-3401829","article-title":"Lymphaticovenous bypass for immediate lymphatic reconstruction in locoregional advanced melanoma patients.","volume":"36","author":"Cakmakoglu","year":"2020","journal-title":"J Reconstr Microsurg"},{"key":"R80-20250501","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/ans.14921","article-title":"Management of in-transit melanoma metastases: a review.","volume":"89","author":"Tie","year":"2019","journal-title":"ANZ J Surg"},{"key":"R81-20250501","doi-asserted-by":"crossref","first-page":"e318","DOI":"10.3747\/co.27.6523","article-title":"Locoregional management of in-transit metastasis in melanoma: an Ontario Health (Cancer Care Ontario) clinical practice guideline.","volume":"27","author":"Wright","year":"2020","journal-title":"Curr Oncol"},{"key":"R82-20250501","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/jso.22029","article-title":"Local and intralesional therapy of in-transit melanoma metastases.","volume":"104","author":"Testori","year":"2011","journal-title":"J Surg Oncol"},{"key":"R83-20250501","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/jso.25400","article-title":"A systematic review and meta-analysis of locoregional treatments for in-transit melanoma.","volume":"119","author":"Read","year":"2019","journal-title":"J Surg Oncol"},{"key":"R84-20250501","first-page":"1234","article-title":"Interleukin-2 for the treatment of melanoma.","volume":"6","author":"Tarhini","year":"2005","journal-title":"Curr Opin Investig Drugs"},{"key":"R85-20250501","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/jso.21968","article-title":"Intra-lesional interleukin-2 for the treatment of in-transit melanoma.","volume":"104","author":"Boyd","year":"2011","journal-title":"J Surg Oncol"},{"key":"R86-20250501","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/jso.23702","article-title":"Treatment of in-transit melanoma with intra-lesional interleukin-2: a systematic review.","volume":"110","author":"Byers","year":"2014","journal-title":"J Surg Oncol"},{"key":"R87-20250501","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1177\/1203475420988862","article-title":"Durability of complete response to intralesional interleukin-2 for in-transit melanoma.","volume":"25","author":"Khouri","year":"2021","journal-title":"J Cutan Med Surg"},{"key":"R88-20250501","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/CCO.0000000000000405","article-title":"Systemic therapy in advanced melanoma.","volume":"29","author":"Silva","year":"2017","journal-title":"Curr Opin Oncol"},{"key":"R89-20250501","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1080\/17512433.2019.1689121","article-title":"Managing in-transit melanoma metastases in the new era of effective systemic therapies for melanoma.","volume":"12","author":"Read","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R90-20250501","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00262-019-02377-x","article-title":"Successful combination therapy of systemic checkpoint inhibitors and intralesional interleukin-2 in patients with metastatic melanoma with primary therapeutic resistance to checkpoint inhibitors alone.","volume":"68","author":"Rafei-Shamsabadi","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"R91-20250501","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.3390\/cancers13081905","article-title":"Contemporary neoadjuvant therapies for high-risk melanoma: a systematic review.","volume":"13","author":"Boulva","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["Plastic &amp; Reconstructive Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PRS.0000000000009936","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T23:04:13Z","timestamp":1746140653000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PRS.0000000000009936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":90,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/prs.0000000000009936","relation":{},"ISSN":["0032-1052"],"issn-type":[{"value":"0032-1052","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,23]]}}}